The Swedish biotech company, MoreinX AB, has entered into a strategic alliance with Brenntag Biosector A/S, a leading producer of vaccine adjuvants.
Vaccine adjuvants are pharmaceutical agents used in vaccines in order to boost the immune response, thereby increasing the efficacy of the vaccine. Brenntag Biosector, located in Frederiksund, Denmark and MoreinX, based in Sweden, Uppsala, will jointly continue the further development and commercialization of a novel formulation of nanoparticles used in vaccine development. These nanoparticles represent the third generation development of immune response stimulating particles originally developed by Professor Bror Morein, an internationally recognized virologist who is also a co-founder of MoreinX AB.
Dr. Erik B. Lindblad, R & D Director of Brenntag Biosector: “These nanoparticles are a very promising supplement to our existing portfolio of high quality vaccine adjuvants. They offer an array of potential new applications for vaccine adjuvants, and in contrast to our existing product portfolio they enable the storing of adjuvant-containing vaccines frozen.”
Lars Monie, Chairman of MoreinX, says, the collaboration with Brenntag Biosector will take the technology closer to the vaccine market.